Sisakian A S, Torgomian A L, Barkhudarian A L
Klin Med (Mosk). 2006;84(10):55-8.
Trimetazidine is a new metabolic antiischemic agent, which increases the tolerance of cardiomyocytes to ischemia. The aim of the study was to evaluate the effect of additional trimatazidine therapy in patients with ischemic cardiomyopathy (ICMP) in comparison with standard therapy of cardiac insufficiency. According to the results of the study, trimetazidine improves the clinical status, functional class of cardiac insufficiency, left ventricular ejection fraction, in ICMP patients. Trimetazidine increases physical exercise tolerance according to the results of six-minute walking test. Thus, the optimization of myocardial energetic metabolism may be a promising perspective in the treatment of coronary heart disease with systolic dysfunction.
曲美他嗪是一种新型代谢性抗缺血药物，可提高心肌细胞对缺血的耐受性。本研究旨在评估与心脏功能不全的标准治疗相比，额外使用曲美他嗪治疗对缺血性心肌病（ICMP）患者的疗效。根据研究结果，曲美他嗪可改善ICMP患者的临床状况、心脏功能不全分级、左心室射血分数。根据六分钟步行试验结果，曲美他嗪可提高身体运动耐量。因此，优化心肌能量代谢可能是治疗收缩功能障碍型冠心病的一个有前景的方向。
